drugset
drugset / Trial / NCT03601819

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

NCT03601819 ↗

Phase 1 Terminated 4 enrolled University of Michigan Rogel Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.

Timeline

Start
2019-05-15
Primary completion
2020-03-07
Completion
2020-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Pacritinib Small molecule 200 mg —

Indications

B-cell chronic lymphocytic leukemia Waldenstrom macroglobulinemia lymphoproliferative syndrome mantle cell lymphoma peripheral T-cell lymphoma, not otherwise specified primary cutaneous T-cell lymphoma